A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib

Tindall, Elizabeth A.; Sharp, John T.; Burr, Aimee M.; Katz, Tiberiu; Wallemark, Carl B.; Verburg, Kenneth M.; Lefkowith, James B.

doi:10.1016/s0149-2918(02)80096-0

Cited by 17 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tindall et al [33] included patients diagnosed with knee OA in a prospective open-label trial. Patients with OA received celecoxib orally at two dosages throughout a 12-month study period.…”

Section: Clinical Studiesmentioning

confidence: 99%

Chondroprotective Actions of Selective COX-2 Inhibitors In Vivo: A Systematic Review

Timur

Caron

Jeuken

et al. 2020

IJMS

View full text Add to dashboard Cite

Knee osteoarthritis (OA) is a condition mainly characterized by cartilage degradation. Currently, no effective treatment exists to slow down the progression of OA-related cartilage damage. Selective COX-2 inhibitors may, next to their pain killing properties, act chondroprotective in vivo. To determine whether the route of administration is important for the efficacy of the chondroprotective properties of selective COX-2 inhibitors, a systematic review was performed according to the PRISMA guidelines. Studies investigating OA-related cartilage damage of selective COX-2 inhibitors in vivo were included. Nine of the fourteen preclinical studies demonstrated chondroprotective effects of selective COX-2 inhibitors using systemic administration. Five clinical studies were included and, although in general non-randomized, failed to demonstrate chondroprotective actions of oral selective COX-2 inhibitors. All of the four preclinical studies using bolus intra-articular injections demonstrated chondroprotective actions, while one of the three preclinical studies using a slow release system demonstrated chondroprotective actions. Despite the limited evidence in clinical studies that have used the oral administration route, there seems to be a preclinical basis for considering selective COX-2 inhibitors as disease modifying osteoarthritis drugs when used intra-articularly. Intra-articularly injected selective COX-2 inhibitors may hold the potential to provide chondroprotective effects in vivo in clinical studies.

show abstract

Section: Clinical Studiesmentioning

confidence: 99%

Chondroprotective Actions of Selective COX-2 Inhibitors In Vivo: A Systematic Review

Timur

Caron

Jeuken

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…They concluded that long-term treatment with this NSAID did not particularly affect the progress of the disease nor did it accelerate the destruction of articular cartilage in OA. 41 The selective action of celecoxib on MMP-3 levels in our own study could be explained by the important role of this enzyme in cartilage metabolism. MMP-3 is capable not only of breaking down many of the elements of the intracellular matrix, such as proteoglycans, gelatins, laminin, fibrinonectin, and type III, IV, IX and X collagen, but also of triggering the activation of other MMPs, such as MMP-1, MMP-7, MMP-8, MMP-9 and MMP-13.…”

Section: Title the Effect Of Non-steroidal Anti-inflammatory Drugs Onmentioning

confidence: 56%

The effect of non-steroidal anti-inflammatory drugs on matrix metalloproteinases levels in patients with osteoarthritis

Efstathiou¹,

Settas²

2017

MJR

View full text Add to dashboard Cite

The objective of this study is to determine and comparatively evaluate the effects of three different non-steroidal anti-inflammatory drugs on the levels of metalloproteinases MMP-1, MMP-3 and MMP-8, as well as on their tissue inhibitor TIMP-1, in patients suffering from idiopathic osteoarthritis. The effect of these drugs on the articular cartilage and the probable use of MMPs and TIMP-1 as markers of disease and treatment was also investigated. METHODS: Thirty-six patients with OA were selected and allocated to three groups on the basis of their disease location. All patients received anti-inflammatory treatment with special selective COX-2 inhibitors, i.e. celecoxib, meloxicam, aceclofenac. Each drug was given to every patient for three months following a randomized order of administration. Serum levels of MMP-1, MMP-3, MMP-8 and TIMP-1, and ratios MMP-1/TIMP-1, MMP-3/TIMP-1, MMP-8/TIMP-1 were measured before and after treatment. RESULTS: The use of aceclofenac resulted in no significant variation in either MMPs concentration and MMPs/TIMP-1 ratio. This outcome concerns the three groups and the 36 patients that form them. After all patients had received all three NSAIDs, MMPs and TIMP-1, these parameters were compared to their initial and final median values. A significant reduction in MMP-3 was found so in all OA patients as in the group of knee OA patients. CONCLUSIONS: 1. Of the MMPs studied, MMP-3 levels were found to be significantly reduced after NSAIDs treatment. Therefore, serum MMP-3 levels in OA patients could be proven to be a useful evaluating marker of treatment on the cartilage level. 2. No significant differences were observed among NSAIDs administered with regards to their effect on MMPs and TIMP-1 concentration.

show abstract

“…No radiographic evidence of disease progression that could be attributed to celecoxib exposure was observed, leading the authors to conclude that long-term therapy with celecoxib does not accelerate OA progression in these joints. 40 This was shown to be true for the knee as well by GAIT. 41…”

Section: Radiographic Progressionmentioning

confidence: 83%

Celecoxib in the Treatment of Osteoarthritis

Battistone

Sawitzke

2010

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

Osteoarthritis is a major cause for pain worldwide and is increasingly so as the number of elderly people continues to grow. Finding treatments that are effective and safe for this pain has been challenging primarily because gastrointestinal risks increase with aging as well. One step in the direction of improvement was the development of selective COX-2 inhibitors, which as a group have lower gastrointestinal adverse reaction rates than traditional non-steroidal anti-inflammatory drugs. However, increases in cardiovascular adverse events with some of these have dampened initial enthusiasm for this approach. One of these inhibitors, celecoxib remains available in most areas of the world for use in pain associated with osteoarthritis. This review illustrates how best to consider it's role in the current treatment of pain associated with arthritis with an emphasis on osteoarthritis.

show abstract

A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib

Cited by 17 publications

References 20 publications

Chondroprotective Actions of Selective COX-2 Inhibitors In Vivo: A Systematic Review

Chondroprotective Actions of Selective COX-2 Inhibitors In Vivo: A Systematic Review

The effect of non-steroidal anti-inflammatory drugs on matrix metalloproteinases levels in patients with osteoarthritis

Celecoxib in the Treatment of Osteoarthritis

Contact Info

Product

Resources

About